Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
760.00K | 1.04M | 4.01M | 4.74M | 1.08M | 71.00K | Gross Profit |
7.00K | -1.75M | 4.01M | 3.35M | -184.00K | -56.93M | EBIT |
-376.73M | -338.85M | -222.61M | -167.88M | -107.70M | -74.95M | EBITDA |
-373.49M | -338.85M | -221.51M | -166.90M | -106.78M | -72.59M | Net Income Common Stockholders |
-328.25M | -298.41M | -214.53M | -159.95M | -106.72M | -72.86M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.27B | 1.35B | 558.55M | 334.43M | 333.71M | 170.88M | Total Assets |
1.36B | 1.43B | 635.35M | 352.18M | 351.01M | 183.44M | Total Debt |
50.82M | 51.72M | 51.73M | 2.02M | 3.07M | 4.01M | Net Debt |
-43.75M | -212.82M | -3.17M | -30.65M | -197.62M | -89.07M | Total Liabilities |
107.33M | 109.79M | 96.25M | 35.85M | 19.07M | 14.53M | Stockholders Equity |
1.25B | 1.32B | 539.11M | -439.17M | -275.25M | -167.61M |
Cash Flow | Free Cash Flow | ||||
-265.32M | -229.81M | -171.00M | -116.86M | -89.02M | -62.21M | Operating Cash Flow |
-261.57M | -225.97M | -166.31M | -115.20M | -88.59M | -62.03M | Investing Cash Flow |
-661.09M | -574.82M | -200.41M | -173.98M | -56.48M | 217.00K | Financing Cash Flow |
621.30M | 1.01B | 388.94M | 121.96M | 252.68M | 114.57M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $3.63B | 15.81 | 37.24% | ― | 22.42% | ― | |
54 Neutral | $5.34B | 3.27 | -45.10% | 3.30% | 16.80% | 0.02% | |
53 Neutral | $2.98B | ― | -30.84% | ― | ― | -1.20% | |
53 Neutral | $2.93B | ― | -14.40% | ― | ― | -23.84% | |
52 Neutral | $2.37B | ― | -103.82% | ― | 48.04% | 48.16% | |
50 Neutral | $3.08B | ― | -106.71% | ― | ― | -22.34% | |
45 Neutral | $2.68B | ― | -62.46% | ― | ― | -43.10% |
At the annual meeting of Crinetics Pharmaceuticals‘ stockholders held on June 11, 2025, key decisions were made, including the election of three Class I directors for three-year terms, the ratification of BDO USA, P.C. as the independent accounting firm, and the approval of executive compensation. These decisions reflect strong shareholder support and are likely to influence the company’s strategic direction and governance structure.
The most recent analyst rating on (CRNX) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.